Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0123

Scientific exchange · Dr. Zoë Castellano

02 May 2026 · Phone · Dr. Zoë Castellano, UCLH · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0123—

Capture insight from this engagement

Location: UCLH
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Patient-reported outcomes
Treatment burden and fatigue

Scientific content used

APRIL-IgAN Phase III topline

Questions raised

What is the immunoglobulin monitoring recommendation?

Notes

Scientific exchange with renal pathologist at UCLH. Discussed patient-reported outcomes, treatment burden and fatigue.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 2
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0123

Audit history (0)

All create, update and approval events for this record

No audit events in sample data